Barinthus Biotherapeutics plc (BRNS)
Automate Your Wheel Strategy on BRNS
With Tiblio's Option Bot, you can configure your own wheel strategy including BRNS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BRNS
- Rev/Share 0.371
- Book/Share 2.5402
- PB 0.5241
- Debt/Equity 0.1171
- CurrentRatio 7.8911
- ROIC -0.0559
- MktCap 53663724.0
- FreeCF/Share -0.9554
- PFCF -1.3923
- PE -0.773
- Debt/Assets 0.0925
- DivYield 0
- ROE -0.5475
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Published: October 03, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholder.
Read More
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Barinthus Biotherapeutics plc (NASDAQ: BRNS) and Clywedog Therapeutics, Inc. is fair to Barinthus shareholders. Under the terms of the agreement, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined.
Read More
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- GERMANTOWN, MD and ALTRINCHAM, UK — September 30, 2025 — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immunology and inflammation company focused on developing therapies that promote immune tolerance, and Clywedog Therapeutics, Inc. (“Clywedog”), a private company advancing novel breakthrough medicines in diabetes, today announced that they have entered into a definitive merger agreement to combine in an all-stock transaction. The newly combined company will advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases, with four clinical data milestones expected within 18 months of the …
Read More
About Barinthus Biotherapeutics plc (BRNS)
- IPO Date 2021-04-30
- Website https://www.barinthusbio.com
- Industry Biotechnology
- CEO William J. Enright MBA
- Employees 105